Replimune Stock Gets BMO Upgrade to Outperform as FDA De-Risks RP1 Approval
PDUFA date set for August 2, 2026.
/ 220 items
#andre↓
Unicycive Therapeutics Receives FDA Complete Response Letter for Resubmitted OLC NDA
The CRL relates to third-party manufacturing issues, but the FDA raised no concerns about clinical efficacy or safety.
The Trade Desk Crushed as Arete Issues One of Wall Street’s Most Bearish Calls
Arete cut The Trade Desk to Sell, citing slowing growth, heavy competition from Amazon/Google, and weak ad demand.
Prime Medicine Gets Analyst Upgrade to Buy as First In Vivo Prime Editing Trial Moves Forward
H.C. Wainwright cites New Zealand clearance for PM577a — the first in vivo Prime Editing clinical trial for Wilson’s disease.
AbbVie and Genmab Report Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Relapsed/Refractory DLBCL
New drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy.
Abivax Shares Surge as Obefazimod Delivers Strong Phase 3 Results in Difficult-to-Treat Ulcerative Colitis
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.